Figure 4: IHS4 score reduction relative to baseline at week 16 (left: Mean, right: Median) for placebo and the high dose group (IFX-1 1200mg q2w). For mean comparisons and the p-value of high dose versus placebo, an ANCOVA model adjusted for IHS4 and Hurley stage at baseline was calculated. The p-value for the median comparison of high dose versus placebo is based on the Wilcoxon rank-sum test. Complete case analysis, no imputation of missing values.
Figure 4: IHS4 score reduction relative to baseline at week 16 (left: Mean, right: Median) for placebo and the high dose group (IFX-1 1200mg q2w). For mean comparisons and the p-value of high dose versus placebo, an ANCOVA model adjusted for IHS4 and Hurley stage at baseline was calculated. The p-value for the median comparison of high dose versus placebo is based on the Wilcoxon rank-sum test. Complete case analysis, no imputation of missing values.